Phosphoinositide 3-kinase signalling in the vascular system

Cardiovascular Research

Volumn 82, Issue 2, 2009, Pages 261-271

  Morello, Fulvio ^a   Perino, Alessia ^a   Hirsch, Emilio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Atherosclerosis; Endothelium; Platelets; Signal transduction; Smooth muscle; Vascular system

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; 5 [5 (4 FLUORO 2 HYDROXYPHENYL)FURFURYLIDENE] 2,4 THIAZOLIDINEDIONE; 9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; ENZYME; NITRIC OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; TGX 211; UNCLASSIFIED DRUG; WORTMANNIN;

ANGIOGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; ENDOTHELIUM CELL; HUMAN; INFLAMMATORY CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; THROMBOCYTE; VASCULAR SMOOTH MUSCLE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HUMANS; ISOENZYMES; MICE; MUSCLE, SMOOTH, VASCULAR; SIGNAL TRANSDUCTION;

EID: 67449152446     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn325     Document Type: Review

References (115)

1. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001; 17: 615-675.
2. Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 2002;90:1243-1250.
3. Hirsch E, Ciraolo E, Ghigo A, Costa C. Taming the PI3K team to hold inflammation and cancer at bay. Pharmacol Ther 2008;118:192-205.
4. Michell BJ, Griffiths JE, Mitchelhill Kl, Rodriguez-Crespo I, Tiganis T, Bozinovski S et al. The Akt kinase signals directly to endothelial nitric oxide synthase. Curr Biol 1999;9:845-848.
5. Kuboki K, Jiang ZY, Takahara N, Ha SW, lgarashi M, Yamauchi Tet al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 2000;101:676-681.
6. Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000;101:1539-1545.
7. lgarashi J, Michel T. Sphingosine 1-phosphate and isoform-specific activation of phosphoinositide 3-kinase beta. Evidence for divergence and convergence of receptor-regulated endothelial nitric-oxide synthase signaling pathways. J Biol Chem 2001;276:36281-36288.
8. di Villa Bianca R, Sorrentino R, Sorrentino R, lmbimbo C, Palmieri A, Fusco F et al. Sphingosine 1-phosphate induces endothelial nitric-oxide synthase activation through phosphorylation in human corpus cavernosum. J Pharmacol Exp Ther 2006;316:703-708.
9. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999;399:601-605.
10. Fulton D, Gratton J-P, McCabe TJ, Fontana J, Fujio Y, Walsh K et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999;399:597-601.
11. Gallis B, Corthals GL, Goodlett DR, Ueba H, Kim F, Presnell SR et al. Identification of flow-dependent endothelial nitric-oxide synthase phosphorylation sites by mass spectrometry and regulation of phosphorylation and nitric oxide production by the phosphatidylinositol 3-kinase inhibitor LY294002. J Biol Chem 1999;274:30101-30108.
12. Dimmeler S, Dernbach E, Zeiher AM. Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett 2000;477:258-262.
13. Dimmeler S, Assmus B, Hermann C, Haendeler J, Zeiher AM. Fluid shear stress stimulates phosphorylation of Akt in human endothelial cells: involvement in suppression of apoptosis. Circ Res 1998;83:334-341.
14. Loufrani L, Retailleau K, Bocquet A, Dumont O, Danker K, Louis H et al. Key role of (alpha)1(beta)1-integrin in the activation of PI3-kinase-Akt by flow (shear stress) in resistance arteries. Am J Physiol Heart Circ Physiol 2008;294:H1906-H1913.
15. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther 2001;299:818-824.
16. Boo YC, Jo H. Flow-dependent regulation of endothelial nitric oxide synthase: role of protein kinases. Am J Physiol Cell Physiol 2003;285: C499-C508.
17. Chen ZP, Mitchelhill KI, Michell BJ, Stapleton D, Rodriguez-Crespo I, Witters LA et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 1999;443:285-289.
18. Boo YC, Sorescu G, Boyd N, Shiojima I, Walsh K, Du J et al. Shear stress stimulates phosphorylation of endothelial nitric-oxide synthase at Ser1179 by Akt-independent mechanisms: role of protein kinase A. J Biol Chem 2002;277:3388-3396.
19. Luo Z, Fujio Y, Kureishi Y, Rudic RD, Daumerie G, Fulton D et al. Acute modulation of endothelial Akt/PKB activity alters nitric oxidedependent vasomotor activity in vivo. J Clin Invest 2000; 106:493-499.
20. Scotland RS, Morales-Ruiz M, Chen Y, Yu J, Rudic RD, Fulton D et al. Functional reconstitution of endothelial nitric oxide synthase reveals the importance of serine 1179 in endothelium-dependent vasomotion. Circ Res 2002;90:904-910.
21. Hurt KJ, Musicki B, Palese MA, Crone JK, Becker RE, Moriarity JL et al. Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection. Proc Natl Acad Sci USA 2002;99:4061- 4066.
22. Ackah E, Yu J, Zoellner S, Iwakiri Y, Skurk C, Shibata R et al. Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. J Clin Invest 2005;115:2119-2127.
23. Andreozzi F, Formoso G, Prudente S, Hribal ML, Pandolfi A, Bellacchio E et al. TRIB3 R84 variant is associated with impaired insulin-mediated nitric oxide production in human endothelial cells. Arterioscler Thromb Vase Biol 2008;28:1355-1360.
24. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 2001;108:1341-1348.
25. Puri KD, Doggett TA, Douangpanya J, Hou Y, Tino WT, Wilson T et al. Mechanisms and implications of phosphoinositide 3-kinase delta in promoting neutrophil trafficking into inflamed tissue. Blood 2004;103: 3448-3456.
26. Puri KD, Doggett TA, Huang CY, Douangpanya J, Hayflick JS, Turner M et al. The role of endothelial PI3Kgamma activity in neutrophil trafficking. Blood 2005;106:150-157.
27. Young LH, lkeda Y, Scalia R, Lefer AM. Wortmannin, a potent antineutrophil agent, exerts cardioprotective effects in myocardial ischemia/ reperfusion. J Pharmacol Exp Ther 2000;295:37-43.
28. Doukas J, Wrasidlo W, Noronha G, Dneprovskaia E, Fine R, Weis S et al. Phosphoinositide 3-kinase 7/S inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc Natl Acad Sci USA 2006; 103: 19866-19871.
29. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form of 'Modified Reperfusion protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 2004;95:230- 232.
30. Serban D, Leng J, Cheresh D. H-ras regulates angiogenesis and vascular permeability by activation of distinct downstream effectors. Circ Res 2008;102:1350-1358.
31. Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vase Biol 2008;28:1584-1595.
32. Potente M, Urbich C, Sasaki K, Hofmann WK, Heeschen C, Aicher A et al. Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization. J Clin Invest 2005;115:2382-2392.
33. Urbich C, Knau A, Fichtischerer S, Walter DH, Bruhl T, Potente M et al. FOXO-dependent expression of the proapoptotic protein Bim: pivotal role for apoptosis signaling in endothelial progenitor cells. Faseb J 2005;19:974-976.
34. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the Pl 3-kinase/Akt pathway. J Clin Invest 2001;108:391-397.
35. Hur J, Yoon CH, Lee CS, Kim TY, Oh IY, Park KW et al. Akt is a key modulator of endothelial progenitor cell trafficking in ischemic muscle. Stem Cells 2007;25:1769-1778.
36. Zeng L, Xiao Q, Margariti A, Zhang Z, Zampetaki A, Patel S et al. HDAC3 is crucial in shear- and VEGF-induced stem cell differentiation toward endothelial cells. J Cell Biol 2006;174:1059-1069.
37. Chavakis E, Carmona G, Urbich C, Gottig S, Henschler R, Penninger JM et al. Phosphatidylinositol-3-kinase-gamma is integral to homing functions of progenitor cells. Circ Res 2008;102:942-949.
38. Madeddu P, Kraenkel N, Barcelos LS, Siragusa M, Campagnolo P, Oikawa A et al. Phosphoinositide 3-kinase gamma gene knockout impairs postischemic neovascularization and endothelial progenitor cell functions. Arterioscler Thromb Vase Biol 2008;28:68-76.
39. Schaper W, Buschmann I. Arteriogenesis, the good and bad of it. Cardiovasc Res 1999;43:835-837.
40. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res 2005;65:550-563.
41. Guo D, Jia Q, Song H-Y, Warren RS, Donner DB. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. J Biol Chem 1995;270: 6729-6733.
42. Xia P, Aiello LP, lshii H, Jiang ZY, Park DJ, Robinson GS et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996;98:2018-2026.
43. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998; 273:30336-30343.
44. Gille H, Kowalski J, Yu L, Chen H, Pisabarro MT, Davis-Smyth T et al. A repressor sequence in the juxtamembrane domain of FIt-I (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3′-kinase activation and endothelial cell migration. EMBOJ 2000;19:4064-4073.
45. Makinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMSO J 2001; 20:4762-4773.
46. Ahmad S, Hewett PW, Wang P, Al-Ani B, Cudmore M, Fujisawa T et al. Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis. Circ Res 2006;99:715-722.
47. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 1998;101:2567-2578.
48. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, lhling C, Technau-lhling K et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003;9: 1370-1376.
49. Yabkowitz R, Meyer S, Black T, Elliott G, Merewether LA, Yamane HK. Inflammatory cytokines and vascular endothelial growth factor stimulate the release of soluble tie receptor from human endothelial cells via metalloprotease activation. Blood 1999;93:1969-1979.
50. Findley CM, Cudmore MJ, Ahmed A, Kontos CD. VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling. Arterioscler Thromb Vase Biol 2007;27:2619-2626.
51. Im E, Kazlauskas A. Regulating angiogenesis at the level of PtdIns-4,5-P2. EMSO J 2006;25:2075-2082.
52. Hong CC, Peterson QP, Hong JY, Peterson RT. Artery/vein specification is governed by opposing phosphatidylinositol-3 kinase and MAP kinase/ERK signaling. Curr Biol 2006;16:1366-1372.
53. Yuan TL, Choi HS, Matsui A, Benes C, Lifshits E, Luo J et al. Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proc Natl Acad Sci USA 2008;105:9739-9744.
54. Graupera M, Guillermet-Guibert J, Foukas LC, Phng LK, Cain RJ, Salpekar A et al. Angiogenesis selectively requires the pHOalpha isoform of PI3K to control endothelial cell migration. Nature 2008; 453:662-666.
55. Heller R, Chang Q, Ehrlich G, Hsieh SN, Schoenwaelder SM, Kuhlencordt PJ et al. Overlapping and distinct roles for PI3K(beta) and (gamma) isoforms in S1P-induced migration of human and mouse endothelial cells. Cardiovasc Res 2008; cvn159.
56. Huang J, Kontos CD. PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects. J Biol Chem 2002; 277:10760-10766.
57. Su JD, Mayo LD, Donner DB, Durden DL. PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment. Cancer Res 2003;63:3585-3592.
58. Hamada K, Sasaki T, Koni PA, Natsui M, Kishimoto H, Sasaki J et al. The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev 2005; 19:2054 2065.
59. Macrez N, Mironneau C, Carricaburu V, Quignard JF, Babich A, Czupalla C et al. Phosphoinositide 3-kinase isoforms selectively couple receptors to vascular L-type Ca(2 + ) channels. Circ Res 2001 ;89:692 699.
60. Viard P, Butcher AJ, HaletG, DaviesA, Nuberg B, Heblich F et al. PI3K promotes voltage-dependent calcium channel trafficking to the plasma membrane. Nat Neurosci 2004;7:939-946.
61. Saward L, Zahrádka P. Angiotensin Il activates phosphatidylinositol 3-kinase in vascular smooth muscle cells. Circ Res 1997;81:249 257.
62. Seki T, Yokoshiki H, Sunagawa M, Nakamura M, Sperelakis N. Angiotensin Il stimulation of Ca2+-channel current in vascular smooth muscle cells is inhibited by lavendustin-A and LY-294002. Pflugers Arch 1999;437: 317-323.
63. Viard P, Exner T, Maier U, Mironneau J, Nurnberg B, Macrez N. Gbetagamma dimers stimulate vascular L-type Ca2+ channels via phosphoinositide 3-kinase. FASEB J 1999;13:685-694.
64. Quignard JF, Mironneau J, Carricaburu V, Fournier B, Babich A, Nurnberg B et al. Phosphoinositide 3-kinase gamma mediates angiotensin II-Induced stimulation of L-type calcium channels in vascular myocytes. J Biol Chem 2001;276:32545-32551.
65. Vecchione C, Patrucco E, Marino G, Barberis L, Poulet R, Aretini A et al. Protection from angiotensin ll-mediated vasculotoxic and hypertensive response in mice lacking PI3Kgamma. J Exp Med 2005;201:1217-1228.
66. Zubkov AY, Rollins KS, Parent AD, Zhang J, Bryan RM. Mechanism of endothelin-1-induced contraction in rabbit basilar artery. Stroke 2000; 31:526-533.
67. Kawanabe Y, Hashimoto N, Masaki T. Effects of phosphoinositide 3-kinase on endothelin-1-induced activation of voltage-independent Ca2+ channels and vasoconstriction. Biochem Pharmacol 2004;68: 215-221.
68. Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S et al. Inhibition of intimai thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999;99:2164-2170.
69. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamyein inhibits vascular smooth muscle cell migration. J Clin Invest 1996; 98:2277 2283.
70. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995;76:412-417.
71. Gregory CR, Huie P, Billingham ME, Morris RE. Rapamycin inhibits arterial intimai thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels. Transplantation 1993;55:1409-1418.
72. Braun-Dullaeus RC, Mann MJ, Seay U, Zhang L, von der Leven HE, Morris RE et al. Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler Thromb Vase Biol 2001;21:1152-1158.
73. Mourani PM, Garl PJ, Wenzlau JM, Carpenter TC, Stenmark KR, Weiser-Evans MCM. Unique, highly proliferative growth phenotype expressed by embryonic and neointimal smooth muscle cells is driven by constitutive Akt, mTOR, and p70S6K signaling and is actively repressed by PTEN. Circulation 2004;109:1299-1306.
74. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IMF et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study. Circulation 2001; 103:192-195.
75. Poon M, Badimon JJ, Fuster V. Overcoming restenosis with sirolimus: from alphabet soup to clinical reality. Lancet 2002;359:619-622.
76. Nemenoff RA, Simpson PA, Furgeson SB, Kaplan-Albuquerque N, Crossno J, Garl PJ et al. Targeted deletion of PTEN in smooth muscle cells results in vascular remodeling and recruitment of progenitor cells through induction of stromal cell-derived factor-!(alpha). Circ Res 2008;102:1036-1045.
77. Huang J, Kontos CD. Inhibition of vascular smooth muscle cell proliferation, migration, and survival by the tumor suppressor protein PTEN. Arterioscler Thromb Vase Biol 2002;22:745-751.
78. Huang J, Niu XL, Pippen AM, Annex BH, Kontos CD. Adenovirus-mediated intraarterial delivery of PTEN inhibits neointimal hyperplasia. Arterioscler Thromb Vase Biol 2005;25:354-358.
79. Koide S, Okazaki M, Tamura M, Ozumi K, Takatsu H, Kamezaki F et al. PTEN reduces cuff-induced neointima formation and proinflammatory cytokines. Am J Physiol Heart Circ Physiol 2007;292:H2824-H2831.
80. 3 gene attenuates murine atherosclerosis. Proc Natl Acad Sci USA 2007;104:8077-8082.
81. Harvey EJ, Li N, Ramji DP. Critical role for casein kinase 2 and phosphoinositide-3-kinase in the interferon-(gamma)-induced expression of monocyte chemoattractant protein-1 and other key genes implicated in atherosclerosis. Arterioscler Thromb Vase Biol 2007;27:806-812.
82. Wang SE, Xiang B, Guix M, Olivares MG, Parker J, Chung CH et al. Transforming growth factor (beta| engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to Trastuzumab. Mol Cell Biol 2008;28: 5605-5620.
83. Pincheira R, Castro AF, Ozes ON, ldumalla PS, Donner DB. Type 1 TNF receptor forms a complex with and uses Jak2 and c-Src to selectively engage signaling pathways that regulate transcription factor activity. J Immunol 2008;181:1288-1298.
84. Hirsch E, Katanaev VL, Garlanda C, Azzolino O, Pirola L, Silengo L et al. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 2000;287:1049-1053.
85. Li Z, Jiang H, Xie W, Zhang Z, Smrčka AV, Wu D. Roles of PLC-2 and -3 and PI3K in chemoattractant-mediated signal transduction. Science 2000; 287:1046-1049.
86. Sasaki T, Irie-Sasaki J, Jones RG, Oliveira-dos-Santos AJ, Stanford WL, Bolon B et al. Function of PI3K in thymocyte development, Tcell activation, and neutrophil migration. Science 2000; 287:1040 1046.
87. Condliffe AM, Davidson K, Anderson KE, Ellson CD, Crabbe T, Okkenhaug K et al. Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 2005;106:1432 1440.
88. Yum H-K, Arcaroli J, Kupfner J, Shenkar R, Penninger JM, Sasaki T et al. Involvement of phosphoinositide 3-kinases in neutrophil activation and the development of acute lung injury. J Immunol 2001; 167:6601 6608.
89. Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, Shaw J et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 2005; 11:936-943.
90. Barber DF, Bartolomee; A, Hernandez C, Flores JM, Redondo C, Fernandez-Arias C et al. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 2005;11:933-935.
91. Fougerat A, Gayral S, Gourdy P, Schambourg A, Ruckle T, Schwarz MK et al. Genetic and pharmacological targeting of phosphoinositide 3-kinase-{gamma) reduces atherosclerosis and favors plaque stability by modulating inflammatory processes. Circulation 2008; 117:1310- 1317.
92. Fernandez-Hernando C, Ackah E, Yu J, Suarez Y, Murata T, Iwakiri Yet al. Loss of Akt1 leads to severe atherosclerosis and occlusive coronary artery disease. Cell Metab 2007;6:446-457.
93. Kasirer-Friede A, Cozzi MR, Mazzucato M, De Marco L, Ruggeri ZM, Shattil SJ. Signaling through GP Ib-IX-Vactivates (alpha)llb(beta)3 independently of other receptors. 6/ood 2004; 103:3403-3411.
94. Jackson SP, Schoenwaelder SM, Yuan Y, Rabinowitz I, Salem HH, Mitchell CA. Adhesion receptor activation of phosphatidylinositol 3-kinase. von Willebrand factor stimulates the cytoskeletal association and activation of phosphatidylinositol 3-kinase and pp60c-src in human 7latelets. JBiol Chem 1994;269:27093-27099.
95. Mu F-T, Andrews RK, Arthur JF, Munday AD, Cranmer SL, Jackson SP et al. A functional 14-3-3(zeta)-independent association of PI3-kinase with glycoprotein Ib(alpha), the major ligand-binding subunit of the platelet glycoprotein Ib-IX-V complex. Blood 2008; 111:4580-4587.
96. Munday AD, Berndt MC, Mitchell CA. Phosphoinositide 3-kinase forms a complex with platelet membrane glycoprotein Ib-IX-V complex and 14-3-3zeta. Blood 2000;96:577-584.
97. Yap CL, Anderson KE, Hughan SC, Dopheide SM, Salem HH, Jackson SP. Essential role for phosphoinositide 3-kinase in shear-dependent signaling between platelet glycoprotein Ib/V/IX and integrin alpha Ibbeta 3. Blood 2002;99:151-158.
98. Hirsch E, Bosco O, Tropel P, Laffargue M, Calvez R, Altruda F et al. Resistance to thromboembolism in PI3K(gamma)-deficient mice. FASEB J 2001;15:2019-2021.
99. Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE et al. Pl 3-kinase pHObeta: a new target for antithrombotic therapy. Nat Med 2005;11:507-514.
100. Yin H, Stojanovic A, Hay N, Du X. The role of Akt in the signaling pathway of the glycoprotein Ib-IX induced platelet activation. Blood 2008;111:658-665.
101. Li Z, Zhang G, Feil R, Han J, Du X. Sequential activation of p38 and ERK pathways by cGMP-dependent protein kinase leading to activation of the platelet integrin (alpha)llbbeta3. Blood 2006;107:965-972.
102. Stojanovic A, Marjanovic JA, Brovkovych VM, Peng X, Hay N, Skidgel RA et al. A phosphoinositide 3-kinase-AKT-nitric oxide-cGMP signaling pathway in stimulating platelet secretion and aggregation. J Biol Chem 2006;281:16333-16339.
103. Bondeva T, Piroe;la L, Bulgarelli-Leva G, Rubio I, Wetzker R, Wymann MP. Bifurcation of lipid and protein kinase signals of PI3K to the protein kinases PKB and MAPK. Science 1998;282:293 296.
104. Banfic H, Tang X-W, Batty IH, Downes CP, Chen C-S, Rittenhouse SE. A novel integrin-activated pathway forms PKB/Akt- stimulatory phosphatidylinositol 3,4-bisphosphate via phosphatidylinositol 3-phosphate in platelets. J Biol Chem 1998;273:13-16.
105. Gironcel D, Racaud-Sultan C, Payrastre B, Horicot M, Borchert G, Kieffer N et al. Alphallbbeta3-integrin mediated adhesion of human platelets to a fibrinogen matrix triggers phospholipase C activation and phosphatidylinositol 3′,4′-bisphosphate accumulation. FESS Lett 1996;389:253-256.
106. Zhang J, Banfic H, Straforini F, Tosi L, Volinia S, Rittenhouse SE. A type II phosphoinositide 3-kinase is stimulated via activated integrin in platelets. A source of phosphatidylinositol 3-phosphate. J Biol Chem 1998;273:14081-14084.
107. Pasquet JM, Bobe R, Gross B, Gratacap MP, Tomlinson MG, Payrastre B et al. A collagen-related peptide regulates phospholipase Cgamma2 via phosphatidylinositol 3-kinase in human platelets. Biochem J 1999; 342:171-177.
108. Watanabe N, Nakajima H, Suzuki H, Oda A, Matsubara Y, Moroi M et al. Functional phenotype of phosphoinositide 3-kinase p85(alpha)-null platelets characterized by an impaired response to GP Vl stimulation. Blood 2003;102:541-548.
109. Lova P, Paganini S, Hirsch E, Barberis L, Wymann M, Sinigaglia F et al. A selective role for phosphatidylinositol 3,4,5-trisphosphate in the Gi-dependent activation of platelet RaplB. J Biol Chem 2003;278: 131-138.
110. Woulfe D, Jiang H, Mortensen R, Yang J, Brass LF. Activation of Rap 1B by Gi family members in platelets. J Biol Chem 2002;277:23382-23390.
111. van der Meijden PE, Schoenwaelder SM, Feijge MA, Cosemans JM, Munnix IC, Wetzker R et al. Dual P2Y 12 receptor signaling in thrombinstimulated platelets-involvement of phosphoinositide 3-kinase beta but not gamma isoform in Ca2+ mobilization and procoagulant activity. FEBS J 2008;275:371- 385.
112. Lian L, Wang Y, Draznin J, Eslin D, Bennett JS, Poncz M et al. The relative role of PLC(beta) and PI3K(gamma| in platelet activation. Blood 2005;106:110-117.
113. Schoenwaelder SM, Ono A, Sturgeon S, Chan SM, Mangin P, Maxwell MJ et al. Identification of a unique co-operative phosphoinositide 3-kinase signaling mechanism regulating integrin (alpha)llbbeta3 adhesive function in platelets. J Biol Chem 2007;282:28648 28658.
114. Patrucco E, Notte A, Barberis L, Selvetella G, Maffei A, Brancaccio M et al. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 2004;118:375-387.
115. Kim S, Garcia A, Jackson SP, Kunapuli SP. Insulin-like growth factor-1 regulates platelet activation through PI3-K(alpha) isoform. Stood 2007;110:4206-4213.